News for STVN Stock

Stevanato Group to Participate in Upcoming Investor Conferences Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025 Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025 Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum Stevanato Group Reports Record Revenue of €1,104 Million for Fiscal Year 2024 Stevanato Group to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 6, 2025 Stevanato Group to Present at Upcoming Investor Conference Stevanato Group to Present at Upcoming Investor Conferences Stevanato Group Reports Financial Results for the Third Quarter of 2024 Stevanato Group Will Introduce Its Large-Volume Vertiva® 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI Milan Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU” Stevanato Group to Present at Upcoming Investor Conferences Stevanato Group Reports Financial Results for the Second Quarter of 2024 Stevanato Group to Report Second Quarter 2024 Financial Results on August 6, 2024 Stevanato Group Unveils New Plant in Cisterna di Latina for the Production of Pre-Sterilized EZ-fill® Syringes and Cartridges Stevanato Group Appoints Franco Stevanato Chief Executive Officer, Succeeding Franco Moro Stevanato Group Announces Results of Annual General Meeting Stevanato Group to Present at Upcoming Investor Conferences Stevanato Group Reports Financial Results for the First Quarter of 2024 Stevanato Group to Present at the Bank of America Securities Healthcare Conference Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024 Stevanato Group appoints Ugo Gay as Chief Operations Officer Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters’ Option to Purchase Additional Ordinary Shares Stevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares Stevanato Group Announces Public Offering of Ordinary Shares Stevanato Group to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum Stevanato Group Delivers Double-Digit Revenue Growth in Fiscal Year 2023 Stevanato Group to Report Fourth Quarter and Year End 2023 Financial Results on March 7, 2024 Stevanato Group Launches EZ-fill® Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and Commercialization Stevanato Group to Present at the 42nd Annual J.P. Morgan Healthcare Conference Stevanato Group's Mavis™ Combi Visual Inspection Machine Selected as Pharma Innovation Award Winner by Pharma Manufacturing Stevanato Group to Present at the Jefferies London Healthcare Conference Stevanato Group Reports Third Quarter 2023 Financial Results Stevanato Group to Report Third Quarter 2023 Financial Results on October 31, 2023 Stevanato Group Announces Voting Results from its Extraordinary General Meeting Stevanato Group to Livestream Inaugural Capital Markets Day on September 27, 2023 Stevanato Group Reports Second Quarter 2023 Financial Results Stevanato Group to Report Second Quarter 2023 Financial Results on July 28, 2023 Stevanato Group Presents Vertiva™, a Versatile On-Body Delivery System Platform for a Wide Range of Injectable Therapies and for Large Delivery Volumes (up to 10mL) Stevanato Group Announces Change in Ex-Dividend Date for its Dividend Stevanato Group to Present at Upcoming Investor Conferences Stevanato Group Reports First Quarter 2023 Financial Results Stevanato Group to Present at BofA Securities Healthcare Conference Stevanato Group to Report First Quarter 2023 Financial Results on May 4, 2023 Stevanato Group Collaborates with Thermo Fisher Scientific to Bring its Innovative On-Body Delivery System Platform to Market Stevanato Group Collaborates with Recipharm to Develop and Manufacture Pre-fillable Syringes for Use in a New Soft Mist Inhaler for the Inhalation of Sensitive Biological Products Stevanato Group to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum Stevanato Group Secures €130 Million ESG-Linked Financing From BNL BNP Paribas and Cassa Depositi e Prestiti to Support Sustainable Global Growth Stevanato Group Reports Fourth Quarter and Fiscal Year 2022 Financial Results Stevanato Group to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 2, 2023 Stevanato Group Collaborates with Transcoject to Provide Pre-Fillable Syringe Polymer Options for Pharma Stevanato Group to Present at Upcoming Investor Conference Stevanato Group Reports Third Quarter 2022 Financial Results Stevanato Group and Gerresheimer AG Present EZ-fill Smart™, a New and Innovative Ready-To-Use Vial Platform Stevanato Group and DWK Life Sciences Sign Non-Exclusive Distribution Agreement for EZ-fill® Platform Products Stevanato Group to Report Third Quarter 2022 Financial Results on November 8, 2022 Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award Stevanato Group to Present at Upcoming Investor Conference Stevanato Group and Gerresheimer AG Announce Collaboration on the Development of an Innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry Stevanato Group Reports Second Quarter 2022 Financial Results Stevanato Group to Report Second Quarter 2022 Financial Results on August 4, 2022 Stevanato Group Releases Sustainability Report 2021, Highlighting the Environmental, Social and Governance (ESG) Performance of the Group Stevanato Group Announces Voting Results from its Annual General Meeting Stevanato Group to Present at Upcoming Investor Conferences Stevanato Group Adding New Capacity in Italy Amid Growing Demand for Its Market-Leading Solutions Stevanato Group Reports First Quarter 2022 Financial Results Stevanato Group Publishes Materials for 2022 Annual General Meeting Stevanato Group and Owen Mumford Sign Exclusive Collaboration Agreement for the Innovative Aidaptus® Auto-Injector Stevanato Group to Report First Quarter 2022 Financial Results on May 10, 2022 Stevanato Group Files Amendment No.1 to Its 2021 Annual Report on Form 20‑F/A Stevanato Group to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum Stevanato Group to Create Manufacturing Hub in China Stevanato Group Reports Record 2021 Revenue of €843.9 million Stevanato Group Announces Agreement With BARDA for the Expansion of Vial Production to Create Industrial Base Capabilities for National Defense Stevanato Group to Report Fourth Quarter Financial Results on March 8, 2022 Stevanato Group Appoints Riccardo Butta as President, Americas Stevanato Group Extends Pen Injector Technology Licensing Agreement With Haselmeier Stevanato Group Announces Expansion of Corporate Headquarters Stevanato Group Reports Strong Third Quarter 2021 Revenue and Financial Results and Updates Full Year 2021 Guidance Stevanato Group to Report Third Quarter Financial Results on November 9 Stevanato Group Wins Pharma Innovation Award For AI-ready Vision Robot Unit (VRU) Stevanato Group Initiates Construction on New U.S. Facility Stevanato Group Announces Second Quarter 2021 Financial Results Stevanato Group Celebrates Initial Public Offering and First Day of Public Trading on New York Stock Exchange (NYSE) Stevanato Group Announces Pricing of Initial Public Offering